Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daniela Miliziano"'
Autor:
Claudia Proto, Sara Manglaviti, Giuseppe Lo Russo, Marco Musca, Giulia Galli, Martina Imbimbo, Matteo Perrino, Nadia Cordua, Eliana Rulli, Zelmira Ballatore, Alessandro Dal Maso, Antonio Chella, Andrea Sbrana, Arsela Prelaj, Roberto Ferrara, Mario Occhipinti, Marta Brambilla, Alessandro De Toma, Laura Mazzeo, Teresa Beninato, Diego Signorelli, Giacomo Massa, Francesca Gabriella Greco, Giuseppina Calareso, Daniela Miliziano, Rosa Maria Di Mauro, Giulia Mella, Alessandra Lucarelli, Angela Paggio, Francesca Galli, Valter Torri, Filippo Guglielmo Maria de Braud, Giulia Pasello, Iacopo Petrini, Rossana Berardi, Monica Ganzinelli, Marina Chiara Garassino, Paolo Andrea Zucali
Publikováno v:
Journal of Thoracic Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2375ed575ffb6584f90354f4af231b2
https://doi.org/10.1016/j.jtho.2023.04.009
https://doi.org/10.1016/j.jtho.2023.04.009
Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers
Autor:
Federico Nichetti, Leonardo Provenzano, Daniela Miliziano, Caterina Sposetti, Chiara Pircher, Marta Bini, Andrea Franza, Giacomo Massa, Monica Niger, Maria Di Bartolomeo, Filippo G. De Braud
Publikováno v:
Journal of Clinical Oncology. 40:e16179-e16179
e16179 Background: Biliary tract cancers (BTCs) are a group of rare tumors with a dismal prognosis and a complex molecular landscape. In this setting, the incidence and clinical relevance of cancer-associated thrombosis (CAT) is unknown, thus BTCs ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bc8e04a740b64ce4a518cca1c4447f6
https://doi.org/10.1200/jco.2022.40.16_suppl.e16179
https://doi.org/10.1200/jco.2022.40.16_suppl.e16179
Autor:
Margherita Nannini, Alessandro Rizzo, Maria Concetta Nigro, Bruno Vincenzi, Alessandro Mazzocca, Giovanni Grignani, Francesco Tolomeo, Lorenzo D'Ambrosio, Giuseppe Badalamenti, Annalisa Bonasera, Elena Fumagalli, Daniela Miliziano, Antonella Brunello, Benedetta Chiusole, Silvia Gasperoni, Marco Novelli, Maria A. Pantaleo
e23521 Background: Regorafenib (REG) is a multikinase inhibitor approved as third-line treatment in gastrointestinal stromal tumors (GIST). Although its proven activity, REG can present a relevant adverse profile which often leads to treatment modifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eedd1661100a7ee52a27efd4cdb32e9e
http://hdl.handle.net/11585/827989
http://hdl.handle.net/11585/827989
